RxDoctor Payments Data

Eron Crouch, MD

Cardiovascular Disease · Corsicana, TXNPI 1275636532

Payments from drug & device makers

$494in general payments, 2019–2025

Across 29 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$116
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$109
  • Biotronik Inc.$43
  • Johnson & Johnson$31
  • Novartis$31
  • Philips North America LLC$30
  • plus $136 from 7 others

What the payments were for

  • Food & beverage$46694%
  • Education$286%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$494 in reported general payments places this provider in the 15th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$110,907
Medicare patients
754
Services billed
1,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban418$376,603
XareltoRivaroxaban172$191,027
EntrestoSacubitril/Valsartan46$56,061
Losartan Potassium491$4,533
Metoprolol Succinate331$4,293
Dabigatran EtexilateDabigatran Etexilate Mesylate13$4,057
Carvedilol474$3,646
Lisinopril449$3,613
Atorvastatin Calcium373$3,288
Clonidine36$3,264
Amlodipine Besylate486$3,084
Metoprolol Tartrate385$2,439
Hydralazine Hcl226$2,114
ClopidogrelClopidogrel Bisulfate181$1,943
Ranolazine ErRanolazine19$1,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$376,603418 claims
Johnson & JohnsonXarelto$31$191,027172 claims
NovartisEntresto$31$56,06146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Corsicana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →